Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT)

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT07462260

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Sindh Institute of Cardiovascular Diseases (from the registry)
Registry
  • NCT NCT07462260
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Pakistan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07462260. Randomized; quadruple masking; primary purpose treatment. Start 2025-08-01 (actual); primary completion 2026-09-23 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT)
Acronym
SERIES
Condition
Rheumatic Valvular Heart Disease
Intervention (Drug)
Sildenafil 25 MG
Intervention (Drug)
Placebo
Lead sponsor
Sindh Institute of Cardiovascular Diseases (class: other)
Collaborator
National Institute of Cardiovascular Diseases (class: not stated)

Record details

Record id
cardio:ct-nct07462260
Content hash
e4d39928d281e57ab892aecd3a38932feab25847ccdf6a9ca5eb2e658e42be19